160 related articles for article (PubMed ID: 38397925)
1. Compensated Advanced Chronic Liver Disease and Steatosis in Patients with Type 2 Diabetes as Assessed through Shear Wave Measurements and Attenuation Measurements.
Barisic-Jaman M; Milosevic M; Skurla V; Dohoczky D; Stojic J; Dinjar Kujundzic P; Cigrovski Berkovic M; Majic-Tengg A; Matijaca A; Lucijanic T; Kardum-Pejic M; Pandzic Jaksic V; Marusic S; Grgurevic I
Biomedicines; 2024 Jan; 12(2):. PubMed ID: 38397925
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic performance of two-dimensional shear wave elastography and attenuation imaging for fibrosis and steatosis assessment in chronic liver disease.
Kobayashi T; Nakatsuka T; Sato M; Soroida Y; Hikita H; Gotoh H; Iwai T; Tateishi R; Kurano M; Fujishiro M
J Med Ultrason (2001); 2024 Jun; ():. PubMed ID: 38951430
[TBL] [Abstract][Full Text] [Related]
3. Two-dimensional shear wave elastography (ElastQ) accurately rules out liver fibrosis and rules in advanced chronic liver disease across liver disease etiologies: a prospective multicenter study.
Bauer DJM; SilvestriI A; Mare R; Maiocchi L; Raimondi A; Semmler G; Mandorfer M; Sporea I; Ferraioli G; Reiberger T
Ultrasonography; 2023 Oct; 42(4):544-554. PubMed ID: 37644806
[TBL] [Abstract][Full Text] [Related]
4. Controlled attenuation parameter reflects steatosis in compensated advanced chronic liver disease.
Piccinni R; Rodrigues SG; Montani M; Murgia G; Delgado MG; Casu S; Stirnimann G; Semmo N; De Gottardi A; Dufour JF; Berzigotti A
Liver Int; 2020 May; 40(5):1151-1158. PubMed ID: 31823449
[TBL] [Abstract][Full Text] [Related]
5. Agreement Between 2-Dimensional Shear Wave and Transient Elastography Values for Diagnosis of Advanced Chronic Liver Disease.
Cassinotto C; Lapuyade B; Guiu B; Marraud des Grottes H; Piron L; Merrouche W; Irles-Depe M; Molinari N; De Ledinghen V
Clin Gastroenterol Hepatol; 2020 Dec; 18(13):2971-2979.e3. PubMed ID: 32348907
[TBL] [Abstract][Full Text] [Related]
6. Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.
Poynard T; Deckmyn O; Peta V; Paradis V; Gautier JF; Brzustowski A; Bedossa P; Castera L; Pol S; Valla D;
Aliment Pharmacol Ther; 2023 Nov; 58(9):888-902. PubMed ID: 37642160
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Performance of Vibration-Controlled Transient Elastography in Liver Transplant Recipients.
Siddiqui MS; Idowu MO; Stromberg K; Sima A; Lee E; Patel S; Ghaus S; Driscoll C; Sterling RK; John B; Bhati CS
Clin Gastroenterol Hepatol; 2021 Feb; 19(2):367-374. PubMed ID: 32272251
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Significance of Controlled Attenuation Parameter in Patients With Compensated Advanced Chronic Liver Disease.
Margini C; Murgia G; Stirnimann G; De Gottardi A; Semmo N; Casu S; Bosch J; Dufour JF; Berzigotti A
Hepatol Commun; 2018 Aug; 2(8):929-940. PubMed ID: 30094404
[TBL] [Abstract][Full Text] [Related]
9. The Prevalence of Liver Steatosis and Fibrosis Assessed by Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter in Apparently Healthy Romanian Medical Students.
Nastasa R; Stanciu C; Zenovia S; Singeap AM; Cojocariu C; Sfarti C; Girleanu I; Chiriac S; Cuciureanu T; Huiban L; Muzica CM; Trifan A
Diagnostics (Basel); 2021 Dec; 11(12):. PubMed ID: 34943578
[TBL] [Abstract][Full Text] [Related]
10. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
[TBL] [Abstract][Full Text] [Related]
11. Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Cao YT; Xiang LL; Qi F; Zhang YJ; Chen Y; Zhou XQ
EClinicalMedicine; 2022 Sep; 51():101547. PubMed ID: 35844772
[TBL] [Abstract][Full Text] [Related]
12. Changes in Transient Elastography with Glucagon-Like Peptide-1 Receptor Agonist Use in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Real-World Retrospective Analysis.
Akhverdyan N; Wieland A; Sullivan S; Lindsay M; Swartwood S; Arndt G; Kaizer LK; Jensen T
Metab Syndr Relat Disord; 2024 Jun; ():. PubMed ID: 38868900
[No Abstract] [Full Text] [Related]
13. Simultaneously Screening for Liver Steatosis and Fibrosis in Romanian Type 2 Diabetes Mellitus Patients Using Vibration-Controlled Transient Elastography with Controlled Attenuation Parameter.
Trifan A; Stratina E; Nastasa R; Rotaru A; Stafie R; Zenovia S; Huiban L; Sfarti C; Cojocariu C; Cuciureanu T; Muzica C; Chiriac S; Girleanu I; Singeap AM; Stanciu C
Diagnostics (Basel); 2022 Jul; 12(7):. PubMed ID: 35885657
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic Performance of 2-D Shear-Wave Elastography with Propagation Maps and Attenuation Imaging in Patients with Non-Alcoholic Fatty Liver Disease.
Podrug K; Sporea I; Lupusoru R; Pastrovic F; Mustapic S; Bâldea V; Bozin T; Bokun T; Salkic N; Șirli R; Popescu A; Puljiz Z; Grgurevic I
Ultrasound Med Biol; 2021 Aug; 47(8):2128-2137. PubMed ID: 33985827
[TBL] [Abstract][Full Text] [Related]
15. Applicability and Results of Liver Stiffness Measurement and Controlled Attenuation Parameter Using XL Probe for Metabolic-Associated Fatty Liver Disease in Candidates to Bariatric Surgery. A Single-Center Observational Study.
Wan T; Köhn N; Kröll D; Berzigotti A
Obes Surg; 2021 Feb; 31(2):702-711. PubMed ID: 32959331
[TBL] [Abstract][Full Text] [Related]
16. Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension.
Semmler G; Stift J; Scheiner B; Wöran K; Schwabl P; Paternostro R; Bucsics T; Stättermayer AF; Pinter M; Ferlitsch A; Trauner M; Reiberger T; Mandorfer M
Dig Dis Sci; 2019 Dec; 64(12):3642-3651. PubMed ID: 31209721
[TBL] [Abstract][Full Text] [Related]
17. Screening for Liver Fibrosis and Steatosis in a Large Cohort of Patients with Type 2 Diabetes Using Vibration Controlled Transient Elastography and Controlled Attenuation Parameter in a Single-Center Real-Life Experience.
Sporea I; Mare R; Popescu A; Nistorescu S; Baldea V; Sirli R; Braha A; Sima A; Timar R; Lupusoru R
J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32268517
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Accuracy and Optimal Cut-off of Controlled Attenuation Parameter for the Detection of Hepatic Steatosis in Indian Population.
Kuchay MS; Choudhary NS; Sharma D; Krishan S; Mishra SK; Wasir JS; Singh MK; Saraf N; Dhampalwar S; Sud R
J Clin Exp Hepatol; 2022; 12(3):893-898. PubMed ID: 35677514
[TBL] [Abstract][Full Text] [Related]
19. Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter for the Diagnosis of Liver Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease.
Zenovia S; Stanciu C; Sfarti C; Singeap AM; Cojocariu C; Girleanu I; Dimache M; Chiriac S; Muzica CM; Nastasa R; Huiban L; Cuciureanu T; Trifan A
Diagnostics (Basel); 2021 Apr; 11(5):. PubMed ID: 33925569
[TBL] [Abstract][Full Text] [Related]
20. Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease.
Scheiner B; Steininger L; Semmler G; Unger LW; Schwabl P; Bucsics T; Paternostro R; Ferlitsch A; Trauner M; Reiberger T; Mandorfer M
Liver Int; 2019 Jan; 39(1):127-135. PubMed ID: 30107095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
